2025 Uzbekistan Medicaments (HS Code 3004) Import: Wild Swings

Key Takeaways

Medicaments, classified under HS Code 3004, exhibited extreme volatility from January to November 2025.

• Market Pulse: Trade values swung wildly, with two massive spikes—July ($606.2M) and September ($559.4M)—amid otherwise stable monthly ranges of $122M-$156M, driven by pre-tariff stockpiling ahead of Uzbekistan’s 2% customs duty.
• Structural Shift: Uzbekistan Medicaments Import relies on a tight trio of suppliers (India, Ukraine, Russia) for 39.53% of volume, blending cost efficiency with latent supply chain fragility.
• Product Logic: HS Code 3004 trade data reveals a market split: 75% retail-ready medicaments (priced $44-$289/unit) dominate, while bulk generics from India anchor low-cost procurement.

This overview covers the period from January to November 2025 and is based on verified customs data from the yTrade database.

Uzbekistan Medicaments (HS Code 3004) Key Metrics Trend

Market Trend Summary

The Uzbekistan Medicaments Import trend from January to November 2025 exhibited extreme volatility, characterized by two sharp, short-lived price spikes amid an otherwise stable pattern. Trade value opened at $156.4 million in January, declined in February, then fluctuated between $122 million and $156 million from March to June. Two massive outliers followed: a surge to $606.2 million in July and another to $559.4 million in September, before values retreated to $147.5 million by November. The overall trajectory for HS Code 3004 was highly unstable, dominated by these two anomalous peaks.

Drivers & Industry Context

The July and September value spikes, which saw unit prices jump over 200%, are best explained by importers front-loading high-value shipments ahead of the new 2% customs duty on pharmaceuticals under HS Code 3004 that took effect April 1, 2025 [Kun.uz]. This policy shift, announced in late January, likely triggered strategic stockpiling of expensive specialty drugs, oncology treatments, and other high-cost medicaments to avoid the additional tariff (Kun.uz). The subsequent sharp corrections in August and October align with a return to regular ordering patterns, though the overall value derived from HS Code 3004 remained elevated compared to early-year levels due to the new cost structure.

Table: Uzbekistan Medicaments Import Trend (Source: yTrade)

Get Uzbekistan Medicaments Data Latest Updates

Uzbekistan HS Code 3004 Import Breakdown

Market Composition & Top Categories

The Uzbekistan HS Code 3004 import market is overwhelmingly dominated by miscellaneous medicaments, accounting for 75% of the total value. According to yTrade data, this category includes mixed or unmixed products for therapeutic uses, packaged for retail sale. Other significant segments involve antibiotics and vitamins, each holding single-digit value shares, while the remaining imports consist of specialized formulations like corticosteroids and hormones.

Value Chain & Strategic Insights

Unit prices for these medicaments range widely from 44 to 289 USD per unit, indicating a specialized market driven by product specificity rather than commodity pricing. High-value items, such as hormone-based treatments, command premium prices, suggesting quality and efficacy are key purchasing factors. This HS Code 3004 breakdown reveals a trade structure focused on finished, retail-ready pharmaceuticals, with imports likely sensitive to regulatory and health standards rather than cost alone.

Table: Uzbekistan HS Code 3004) Import Breakdown Details (Source: yTrade)

Check Detailed HS Code 3004 Breakdown

Uzbekistan Medicaments Origin Countries

Supplier Concentration & Dependency

Uzbekistan's Medicaments import sources throughout most of 2025 are diversified, with no single country holding a monopoly. The supply is controlled by a trio of key players: India (16.34% of total value), Ukraine (12.10%), and Russia (11.09%). This spread across three primary origins indicates a strategic effort to mitigate over-reliance on any single nation, though the combined 39.53% share from these suppliers represents a significant dependency.

Procurement Strategy & Supply Chain Logic

The supply chain for major suppliers of Medicaments is built for cost efficiency, not technical performance. India’s value share (16.34%) is substantially lower than its weight share (24.87%), a clear indicator of low unit prices consistent with sourcing generic or bulk pharmaceuticals. This strategy prioritizes high-volume, low-cost procurement to meet broad population health needs rather than investing in high-value, specialized treatments.

Table: Uzbekistan Medicaments (HS Code 3004) Top Origin Countries (Source: yTrade)

Get Uzbekistan Medicaments (HS Code 3004) Complete Origin Countries Profile

Uzbekistan Medicaments Supplier Companies Analysis

Supplier Concentration & Market Structure

According to yTrade data, Uzbekistan's import market for Medicaments under HS Code 3004 is overwhelmingly dominated by key suppliers, who account for 73.75% of the total import value. This structure indicates a supply chain that is highly integrated and reliant on stable Tier-1 manufacturers, such as CHEMICAL WORKS OF GEDEON RICHTER PLC and KUSUM HEALTHCARE PVT. LTD. These major suppliers for Medicaments form the anchor of Uzbekistan's import sources, ensuring consistent volume and value flow.

Sourcing Reliability & Risk Profile

The high-frequency engagement with these key partners points to a Just-in-Time inventory model, demanding exceptional logistics reliability to maintain supply continuity. This operational strategy faces a new cost pressure, as [Uzbekistan introduced a 2% customs duty on these imports effective April 2025], which will impact procurement costs throughout most of 2025. The sourcing patterns for HS Code 3004 thus blend stable partnerships with emerging fiscal risks, requiring careful cost management alongside logistical precision.

Table: Uzbekistan Medicaments (HS Code 3004) Top Suppliers List (Source: yTrade)

Check Full Uzbekistan Medicaments Suppliers list

Action Plan for Medicaments Market Operation and Expansion

• Diversify suppliers: Reduce reliance on India, Ukraine, and Russia by vetting alternative manufacturers in Turkey or China to mitigate geopolitical and tariff risks.
• Lock in contracts: Secure fixed-price agreements with Tier-1 suppliers like Gedeon Richter before 2026 to hedge against post-tariff cost inflation.
• Optimize logistics: Shift high-volume, low-value generics to rail or consolidated shipping to offset the 2% duty’s impact on margin.
• Monitor regulatory alerts: Track Uzbekistan’s customs updates for further duty adjustments, which could trigger another stockpiling cycle.
• Target premium niches: Expand high-value medicament imports (e.g., hormone therapies) with technical documentation to justify premium pricing post-tariff.

Take Action Now —— Explore Uzbekistan Medicaments HS Code 3004 Import Data

Frequently Asked Questions

Q1. What is driving the recent changes in Uzbekistan Medicaments Import in 2025?

The extreme volatility in 2025, including two sharp price spikes, was driven by importers stockpiling high-value medicaments ahead of a new 2% customs duty. The July and September surges reflect strategic front-loading of specialty drugs like oncology treatments, followed by a return to regular ordering patterns.

Q2. Who are the main origin countries of Uzbekistan Medicaments (HS Code 3004) in 2025?

India (16.34%), Ukraine (12.10%), and Russia (11.09%) dominate Uzbekistan’s medicaments imports, collectively supplying 39.53% of the total value. This diversified sourcing mitigates over-reliance on any single country.

Q3. Why does the unit price differ across origin countries of Uzbekistan Medicaments Import?

Price differences stem from product specialization, with high-value items like hormone-based treatments commanding premiums (up to $289/unit). India’s lower unit prices reflect its focus on generic or bulk pharmaceuticals, while others supply niche formulations.

Q4. What should importers in Uzbekistan focus on when buying Medicaments?

Importers must balance cost efficiency with supply chain reliability, given the 2% duty increase and dependence on key suppliers like Gedeon Richter and Kusum Healthcare. Prioritizing logistics stability and cost management is critical amid fiscal pressures.

Q5. What does this Uzbekistan Medicaments import pattern mean for overseas suppliers?

Suppliers face a market prioritizing both volume (via India’s generics) and high-value specialty drugs. Stable partnerships with Uzbek importers offer opportunities, but price sensitivity and regulatory compliance remain key challenges.

Q6. How is Medicaments typically used in this trade flow?

Imports under HS Code 3004 are primarily retail-ready pharmaceuticals, including therapeutic medicaments (75% of value), antibiotics, and vitamins. The focus is on finished products meeting health standards rather than raw materials.